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BACKGROUND
Artemisinin-based combination therapies are the recommended first-line treatments 
of falciparum malaria in all countries with endemic disease. There are recent con-
cerns that the efficacy of such therapies has declined on the Thai–Cambodian 
border, historically a site of emerging antimalarial-drug resistance.
METHODS
In two open-label, randomized trials, we compared the efficacies of two treatments 
for uncomplicated falciparum malaria in Pailin, western Cambodia, and Wang Pha, 
northwestern Thailand: oral artesunate given at a dose of 2 mg per kilogram of 
body weight per day, for 7 days, and artesunate given at a dose of 4 mg per kilogram 
per day, for 3 days, followed by mefloquine at two doses totaling 25 mg per kilogram. 
We assessed in vitro and in vivo Plasmodium falciparum susceptibility, artesunate 
pharmaco kinetics, and molecular markers of resistance.
RESULTS
We studied 40 patients in each of the two locations. The overall median parasite 
clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours 
(interquartile range, 36 to 66) in Wang Pha (P<0.001). Recrudescence confirmed by 
means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiv-
ing artesunate monotherapy and 1 of 20 (5%) receiving artesunate–mefloquine therapy 
in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), respectively, in Wang 
Pha (P = 0.31). These markedly different parasitologic responses were not explained 
by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of 
isotopic in vitro sensitivity tests, or putative molecular correlates of P. falciparum 
drug resistance (mutations or amplifications of the gene encoding a multidrug re-
sistance protein [PfMDR1] or mutations in the gene encoding sarco–endoplasmic 
reticulum calcium ATPase6 [PfSERCA]). Adverse events were mild and did not differ 
significantly between the two treatment groups.
CONCLUSIONS
P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as 
compared with northwestern Thailand. Resistance is characterized by slow parasite 
clearance in vivo without corresponding reductions on conventional in vitro suscep-
tibility testing. Containment measures are urgently needed. (ClinicalTrials.gov num-
ber, NCT00493363, and Current Controlled Trials number, ISRCTN64835265.)
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A rtemisinins are established anti-malarial agents with an excellent safety profile.1 Artemisinin-based combination 
therapies are now recommended by the World 
Health Organization (WHO) as first-line treat-
ment of uncomplicated falciparum malaria in all 
areas in which malaria is endemic.2 Replacing in-
effective, failing treatments (chloroquine and sul-
fadoxine–pyrimethamine) with artemisinin-based 
combination therapies has reduced the morbidity 
and mortality associated with malaria.3-5 Paren-
teral artesunate is replacing quinine for the treat-
ment of severe malaria.6 Recently, there have been 
signs that the efficacy of artemisinin-based com-
bination therapy and artesunate monotherapy have 
declined in western Cambodia.7-10 Artemisinin 
resistance would be disastrous for global malaria 
control. To characterize treatment responses to 
artemisinin derivatives and provide evidence for 
planning containment-measure strategies, WHO 
and the National Malaria Control Programmes of 
Cambodia and Thailand established a multipar-
tite task force. The trials reported here were con-
ducted as part of this initiative.
Me thods
Study design
We conducted two open-label, randomized, clin-
ical, parasitologic, and pharmacokinetic studies to 
compare therapeutic responses to artesunate in 
Pailin, western Cambodia, where artemisinins 
have been used for more than 30 years, and at the 
northwestern Thai–Burmese border, a region 
where artemisinin-based combination therapies 
were first deployed11 in 1994 and remain highly 
effective.5 The study was monitored externally. 
Approval for the study design was obtained from 
the Ministry of Health in Cambodia, the Ethics 
Committee of the Faculty of Tropical Medicine of 
Mahidol University in Thailand, the Oxford Trop-
ical Medicine Ethical Committee, the WHO Re-
search Ethics Review Committee, and the Techni-
cal Review Group of the WHO Western Pacific 
Regional Office.
Study Sites and Patients
The studies were conducted in Pailin Referral Hos-
pital in western Cambodia and in the Shoklo Ma-
laria Research Unit (SMRU) clinic in Wang Pha, 
Tak Province, northwestern Thailand. Malaria 
transmission is low and seasonal in both sites.12 
In Pailin, children over 5 years of age and nonpreg-
nant adults with uncomplicated falciparum malaria 
(parasite density, ≥10,000 per cubic millimeter of 
blood at the time of screening) were enrolled if 
written informed consent had been obtained from 
the patient or, if a child, from a parent or guard-
ian. The study in Wang Pha, Thailand, started later, 
but the Ethics Committee of the Faculty of Trop-
ical Medicine of Mahidol University did not ap-
prove the enrollment of children, so only nonpreg-
nant adults and children at least 16 years of age 
were enrolled, after written informed consent had 
been provided by the patient or, if a child, by a 
parent or guardian. Patients with severe disease,2 
coinfection, infection with other malaria species, 
antimalarial-drug use within 48 hours before en-
rollment, or known allergies to artesunate or mef-
loquine were excluded. 
Drug Therapy
Patients were randomly assigned, in blocks of 10, 
to receive either artesunate (Guilin Pharmaceuti-
cal, with repacking and quality control by Sanofi-
Synthelabo for distribution in Cambodia and by 
Atlantic for distribution in Thailand) or artesu-
nate plus mefloquine (Medochemie for Cambodia 
and MephaPharma for Thailand). The artesunate 
monotherapy was administered as 2 mg per kilo-
gram of body weight per day, orally, for 7 days. 
The artesunate–mefloquine therapy was admin-
istered as artesunate at a dose of 4 mg per kilo-
gram per day, orally, for 3 days, plus mefloquine 
at a dose of 15 mg per kilogram on day 3 and 10 mg 
per kilogram on day 4.
Opaque envelopes contained the unique study 
numbers of the patients, with the numbers refer-
ring to numbered allocated antimalarial treat-
ments stored in an opaque, hard-cover box. Drug 
administration was directly observed. If vomiting 
occurred within 30 minutes after administration, 
the full dose was repeated; if it occurred between 
30 and 60 minutes after administration, half the 
dose was given. The use of antibiotics with anti-
malarial activity was avoided. All patients were 
hospitalized for 7 days.
Clinical Procedures
A full clinical history was obtained on admission 
to the hospital, and a physical examination and 
blood collection were carried out. Tympanic tem-
perature was recorded every 6 hours. Fever clear-
ance times were defined as the time to the first 
temperature reading of less than 37.5°C and the 
time to the start of the first 24-hour period during 
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which the temperature remained below 37.5°C. 
Adverse events were recorded on a standard form. 
Parasite asexual stages and gametocyte counts 
were determined at 0, 4, 8, and 12 hours and then 
every 6 hours until two consecutive slides were 
free of asexual parasites. The parasite clearance 
time was defined as the time from the start of 
treatment until the first negative blood smear. 
Parasite-reduction ratios were calculated as 100 
minus the percentage reduction from the base-
line level.
Follow-up Evaluations
Patients were assessed weekly until day 63 after 
enrollment and were advised to return if they felt 
unwell. Blood specimens were collected on en-
rollment and at the time of any recurrent para-
sitemia, for purposes of parasite genotyping. DNA 
extraction and purification were performed with 
the use of a standardized kit (QIAamp DNA Mini 
Kit, Qiagen). Amplification and analysis were 
performed as described previously.13 Polymor-
phisms in genes encoding the surface proteins of 
the Plasmodium falciparum merozoite (MSP-1 and 
MSP-2) and the glutamate-rich protein (GLURP) 
were compared between samples obtained before 
and after treatment to distinguish reinfection from 
recrudescence.14
Recurrent P. falciparum infection was treated in 
the artesunate-monotherapy group with artesu-
nate at a dose of 4 mg per kilogram per day, and 
in the artesunate–mefloquine group with artesu-
nate at a dose of 6 mg per kilogram per day, 
combined with doxycycline at a dose of 3.5 mg 
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Figure 1. Enrollment, Randomization, and Follow-up of the Patients in the Two Studies.
Mixed infection was infection with Plasmodium vivax and P. falciparum.
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Table 1. Baseline Characteristics of the Study Patients, According to Location.*
Characteristic Wang Pha, Thailand Pailin, Cambodia
P Value for Wang Pha 
vs. Pailin
Artesunate 
Monotherapy 
(N = 20)
Artesunate–
Mefloquine 
(N = 20)
Artesunate 
Monotherapy 
(N = 20)
Artesunate–
Mefloquine 
(N = 20)
Male sex — no. (%) 19 (95) 20 (100) 15 (75) 16 (80) 0.01
Weight — kg 0.001†
Median 55 51 47 47
Range 35–66 39–59 21–60 21–62
Age — yr 0.008
Mean 31 30 27 22
95% CI 28–35 26–34 21–33 16–27
Temperature — °C <0.001
Median 37.9 37.3 38.5 38.5
95% CI 37.6–38.3 36.9–37.7 38.1–38.9 38.1–38.9
Hemoglobin — g/dl 0.21
Median 12.5 12.4 11.8 12.0
95% CI 11.7–13.3 11.6–13.3 10.8–12.8 10.9–13.1
White-cell count — ×10−3/mm3 0.71†
Median 5.6 5.8 5.3 6.2
Range 2.0–13.4 2.8–12.2 3.7–8.9 3.3–11.9
Platelet count — ×10−3/mm3 0.19†
Median 121 104 82 114
Range 47–410 29–357 17–357 40–383
Glucose — mg/dl <0.001†
Median 116 108 98 97
Range 96–169 89–197 74–186 74–184
Creatinine — mg/dl 0.02†
Median 0.98 0.97 0.85 0.81
95% CI 0.90–1.06 0.89–1.04 0.75–0.95 0.66–0.95
Bilirubin — mg/dl <0.001
Geometric mean 1.00 0.94 1.53 1.57
95% CI 0.74–1.34 0.75–1.19 1.26–1.87 1.29–1.92
Alanine aminotransferase — U/liter 0.15†
Median 24 27 26 17
Range 7–110 7–50 8–80 6–40
Aspartate aminotransferase — U/liter <0.001†
Median 25 30 45 38
Range 12–130 15–51 30–149 29–65
Alkaline phosphatase — U/liter <0.001†
Median 68 79 108 92
Range 33–148 43–118 54–226 63–268
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 13, 2014. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Artemisinin-Resistant Plasmodium Falciparum Malaria
n engl j med 361;5 nejm.org july 30, 2009 459
per kilogram per day in patients 8 years of age 
or older or clindamycin at a dose of 10 mg per 
kilogram twice a day in younger children. All 
these regimens were 7 days in duration.
Pharmacokinetics of Artesunate  
and Dihydroartemisinin
Venous-blood specimens were obtained at 0, 0.25, 
0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 hours after the 
first artesunate dose. In Pailin, the samples were 
collected on ice in prechilled fluoride–oxalate 
tubes. After methodologic investigations,15 the 
tubes were changed to prechilled lithium–hepa-
rin tubes for the Thailand study. Samples were 
centrifuged at 4°C and stored in liquid nitrogen 
until analysis. Plasma concentrations of artesu-
nate and dihydroartemisinin (the active metabo-
lite of artesunate) were measured by means of 
high-throughput liquid chromatography–tandem 
mass spectrometry after solid-phase extraction.16 
Artesunate and dihydroartemisinin labeled with 
a stable isotope were used as internal standards. 
The coefficients of variation for all quality-con-
trol samples were less than 5% at all drug con-
centrations. Pharmacokinetics were characterized 
through noncompartmental analysis, with the use 
of WinNonlin software, version 5.0 (Pharsight). 
Artesunate and dihydroartemisinin concentrations 
at the Cambodian site were multiplied by 1.09 to 
adjust for the different anticoagulants used at the 
Thai site.15 We report the observed maximum 
plasma concentrations of artesunate and dihy-
droartemisinin and the observed times to the 
maximum concentration.
In Vitro Testing of Antimalarial-Drug 
Susceptibility
In vitro testing of drug sensitivity was performed 
in parasites freshly obtained from the study pa-
tients at the Institute Pasteur laboratories (Phnom 
Penh, Cambodia) and at SMRU (Mae Sot, Thailand) 
by means of the standard 48-hour 3H-hypoxan-
thine uptake inhibition method.17 The laboratory-
adapted strain 3D7 was used as a reference. The 
50% inhibitory concentration was determined with 
the use of log-probit approximation, to fit the con-
centration–inhibition data.
Molecular Markers of Antimalarial-Drug 
Resistance
Copy numbers of the P. falciparum multidrug-resis-
tance gene PfMDR1 were assessed by means of a 
real-time polymerase-chain-reaction (PCR) assay 
(Taqman) involving previously described primers 
Table 1. (Continued.)
Characteristic Wang Pha, Thailand Pailin, Cambodia
P Value for Wang Pha 
vs. Pailin
Artesunate 
Monotherapy 
(N = 20)
Artesunate–
Mefloquine 
(N = 20)
Artesunate 
Monotherapy 
(N = 20)
Artesunate–
Mefloquine 
(N = 20)
Albumin — g/dl 0.22
Median 3.8 3.8 3.5 3.8
95% CI 3.6–4.0 3.6–4.0 3.3–3.7 3.6–4.0
Parasite density — no./mm3 <0.001
Geometric mean 37,214 22,746 64,166 65,299
95% CI 26,391–52,477 13,888–37,252 39,155–105,153 40,813–104,474
Presence of gametocytes — no. (%) 6 (30) 5 (25) 5 (25) 6 (30) 1.00
* In Pailin, Cambodia, children older than 5 years of age were included, whereas in Wang Pha, Thailand, children 16 years of age or older and 
adults were enrolled. Artesunate monotherapy consisted of oral artesunate at a dose of 2 mg per kilogram of body weight per day for 7 days. 
Artesunate–mefloquine therapy consisted of oral artesunate at a dose of 4 mg per kilogram per day for 3 days, followed by mefloquine at a 
dose of 15 mg per kilogram on day 3 after admission and 10 mg per kilogram on day 4 after admission. The data are listed separately for 
children and adults in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org. To convert values for 
glucose to millimoles per liter, multiply by 0.05551. To convert values for creatinine to micromoles per liter, multiply by 88.4. To convert val-
ues for bilirubin to micromoles per liter, multiply by 17.1. CI denotes confidence interval.
† The P value was calculated with the use of the Mann–Whitney U test.
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and probes.18 The P. falciparum 3D7 strain was used 
as an external control, and the gene encoding 
β-tubulin as an internal control. Polymorphisms 
in PfMDR1 and the gene encoding P. falciparum 
chloroquine resistance transporter (PfCRT) were 
assessed with the use of a PCR restriction-frag-
ment-length–polymorphism assay or direct gene 
sequencing. The gene encoding sarco–endoplas-
mic reticulum calcium ATPase6 (PfSERCA) was 
amplified by means of PCR and then directly se-
quenced. Analysis was performed with Bioedit 
software.
Statistical Analysis
We calculated that we would need to enroll 40 
patients at each of the two study sites to allow for 
the detection of a difference between the propor-
tions of patients in whom parasitemia persists 
after 72 hours after the start of treatment in Wang 
Pha, Thailand (4%, on the basis of historical data), 
and Pailin, Cambodia (expected to be at least 25%), 
with a significance level of 5% and a statistical 
power of 80%. Data were analyzed by means of 
Student’s t-test, the chi-square test, or the Mann–
Whitney U test, as appropriate. Parasite clearance 
times, fever clearance times, and the duration of 
gametocyte carriage were assessed by means of 
survival analysis with the use of the Kaplan–Meier 
method and the Wilcoxon–Breslow–Gehan test. 
Rates of gametocyte carriage were calculated as 
the total carriage time per total person-weeks of 
follow-up. To adjust for the higher parasite load 
at baseline in Pailin, the analysis was stratified 
according to the log10-normalized parasite load, 
with strata of less than 5.00 and 5.00 or more. 
Multivariate regression was also performed, with 
parasite clearance time as the dependent variable 
and study site and baseline parasite density as 
independent variables. Linear regression model-
ing was performed with the use of serial log para-
site counts to estimate the times to clearance of 
50% and 90% of the parasite load for each patient. 
All analyses were performed with the use of Stata 
software, version 10 (StataCorp).
R esult s
Between June 2007 and May 2008, a total of 80 
patients were enrolled: 40 in Pailin, of whom 11 
(28%) were under 16 years of age, and 40 in Wang 
Pha, where children were not enrolled (Fig. 1 and 
Table 1, and Table S1 in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). The number of days of fever before 
enrollment was similar in Pailin (median, 3 days; 
range, 1.5 to 8) and in Wang Pha (median, 2 days; 
range, 1 to 6) (P = 0.21).
Parasitologic and Clinical Responses
Parasite clearance was markedly slower in Pailin 
(Table 2), with a median parasite clearance time 
for both Pailin treatment groups combined of 84 
hours (interquartile range, 60 to 96), as compared 
with 48 hours (interquartile range, 36 to 66) in 
both Wang Pha groups (P<0.001). After the start 
of treatment in Pailin, 73% of patients had para-
sitemia at 48 hours, 55% at 72 hours, and 20% at 
96 hours; the corresponding percentages in Wang 
Pha were 45%, 8%, and 3% (P<0.001). In Pailin, 
the parasite density at baseline was similar in chil-
dren under 16 years of age (geometric mean, 50,046 
per cubic millimeter; 95% confidence interval [CI], 
22,767 to 110,007) and in children at least 16 years 
of age and adults (geometric mean, 71,366 per 
cubic millimeter; 95% CI, 49,614 to 102,654) 
(P = 0.33). In Pailin, the median parasite clear-
ance time among the 11 children was 78 hours 
(interquartile range, 60 to 96), as compared with 
84 hours (interquartile range, 66 to 96) among 
the 29 adults and children at least 16 years of age 
(P = 0.67). To assess whether exclusion of children 
from the Wang Pha, Thailand, study influenced 
the results, data from the Cambodian children were 
excluded from the analysis; the difference in par-
asite clearance times between the two study sites 
remained significant (P<0.001) (Table S2 in the 
Supplementary Appendix). We also compared the 
parasite clearance times as calculated on the ba-
sis of daily parasite counts in 3264 patients (1996 
adults and children at least 16 years of age, and 
1268 children under 16 years of age) in the Thai-
land study area between 1995 and 2007, as well 
as the times as calculated on the basis of counts 
every 6 hours in 1214 patients with hyperpara-
sitemia (449 adults and children at least 16 years 
of age, and 765 children under 16 years of age) 
who were treated with artesunate-containing regi-
mens. After adjustment for parasitemia, study lo-
cation, and year of admission, there was no signifi-
cant difference for children under 16 years of age 
as compared with adults and children at least 16 
years of age in parasite clearance times (P>0.20 for 
all comparisons).
The difference in parasite clearance times also 
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remained significant when the analysis was strat-
ified according to the log10-normalized parasite 
density on admission (P = 0.008). Further analysis 
involving linear regression, adjusted for baseline 
parasite density, showed that site was a significant 
independent predictor of the time to parasite clear-
ance, whether children were included in the model 
(coefficient, 18.1; 95% CI, 8.9 to 27.2; P<0.001) 
or excluded from the model (coefficient, 18.7; 
95% CI, 8.0 to 29.4; P = 0.001). Other measures 
of parasite reduction that are less dependent on 
the initial parasite load, including the parasite-
reduction ratios after 24 and 48 hours and the 
slope of the log10-normalized parasite clearance 
over time, were also markedly different between 
the study sites (Table 2 and Fig. 2).
In Pailin, there was no evident dose–response 
relationship for artesunate: the median parasite 
clearance time was 84 hours (interquartile range, 
54 to 96) for the dose of 2 mg per kilogram and 
72 hours (interquartile range, 60 to 96) for the 
dose of 4 mg per kilogram (P = 0.61). In contrast, 
in Wang Pha, patients treated with artesunate at 
a dose of 4 mg per kilogram had faster parasite 
clearance (median, 48 hours; interquartile range, 
30 to 54) than those treated with artesunate at a 
dose of 2 mg per kilogram (median, 54; inter-
quartile range, 42 to 72) (P = 0.02) (Table 2).
Fever clearance times did not differ signifi-
cantly between the two study sites (Table 2). Early 
treatment failure, defined as parasitemia and fe-
ver persisting for more than 3 days (≥72 hours) 
after the start of treatment,2 occurred in 3 of the 
40 patients (8%) in Pailin, as compared with none 
in Wang Pha (P = 0.20). In the artesunate-mono-
therapy group, late parasitologic failure (defined 
as PCR-confirmed recrudescence of P. falciparum 
infection >7 days after the start of treatment)2 oc-
curred in 6 of the 20 patients (30%) in Pailin after 
a median of 28 days (range, 21 to 35) and in 2 of 
the 20 patients (10%) in Wang Pha, after 21 days 
for both patients. In the artesunate–mefloquine 
group, there were no occurrences of early treat-
ment failure, and late parasitologic failure occurred 
in 1 of the 20 patients (5%) at each site, after 49 
days in Pailin and 34 days in Wang Pha. Reinfec-
tion was more common in Wang Pha than in 
Pailin (P = 0.001) (Table 2). Recurrent infection 
with P. vivax was common at both study sites. 
The median duration of patent gametocytemia per 
person-weeks of follow-up was 0.06 weeks (95% 
CI, 0.05 to 0.07) in Wang Pha and 0.07 weeks 
(95% CI, 0.06 to 0.08) in Pailin (P = 0.13). The 
duration of gametocyte carriage in patients who 
had gametocytemia at any time also did not dif-
fer significantly between the sites (Table 2).
The number of patients reporting an adverse 
event did not differ significantly between the two 
treatment groups (Table S3 in the Supplementary 
Appendix). Dizziness, joint pain, muscle pain, and 
sleepiness were more common in Wang Pha, 
whereas nausea, abdominal pain, and fatigue were 
reported more frequently in Pailin. No serious ad-
verse events were observed.
Pharmacokinetics
Body-weight–normalized doses of the study drugs 
were similar at the two study sites. Plasma-con-
centration profiles of artesunate and dihydroar-
temisinin, and the pharmacokinetic variables de-
rived from them, were generally similar at the 
two sites, although the areas under the concen-
tration–time curves were slightly greater in Pailin 
(Table 3). There was no significant correlation 
between the maximum concentration of artesu-
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Figure 2. Parasite Clearance Curves.
The data are log10-normalized median parasite densities over time among 
the 20 patients in each treatment group. The T bars indicate half of the in-
terquartile ranges. Artesunate monotherapy consisted of artesunate at a 
dose of 2 mg per kilogram of body weight for 7 days. Artesunate–meflo-
quine therapy consisted of artesunate at a dose of 4 mg per kilogram for  
3 days followed by mefloquine at a dose of 15 mg per kilogram on day 3 
after admission and 10 mg per kilogram on day 4 after admission.
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nate or dihydroartemisinin, or the area under the 
concentration–time curve, and measures of para-
site clearance (parasite clearance time and para-
site-reduction ratios after 24 and 48 hours) or the 
risk of treatment failure (Fig. S1 in the Supple-
mentary Appendix). Exclusion of children from 
the analysis did not affect these findings.
In Vitro Sensitivity Testing
Reliable fitting of the hypoxanthine-uptake curves 
for artesunate and dihydroartemisinin was pos-
sible for 18 of the 40 patients for both drugs in 
Pailin and 32 of 40 patients and 30 of 40 pa-
tients, respectively, in Wang Pha. The median 
50% inhibitory concentration of artesunate in 
Table 3. Results of Noncompartmental Analysis of First-Dose Pharmacokinetics, According to Study Drug.*
Variable Wang Pha, Thailand Pailin, Cambodia P Value for Wang Pha vs. Pailin
Artesunate 
Monotherapy
(N=20)
Artesunate–
Mefloquine 
(N=20)
Artesunate 
Monotherapy
 (N=20)
Artesunate–
Mefloquine 
(N=19)
Both 
Treatment 
Groups
Artesunate 
Monotherapy
Artesunate–
Mefloquine
Dose (mg/kg)
Median 2.03 4.03 2.01 3.95 0.41 0.81
Range 1.81–2.14 3.85–4.09 1.83–2.33 3.80–4.17
Artesunate
Maximum plasma drug concentration (nM)
Median 444 522 702 822 0.47 0.09
Range 83–1300 120–3720 79–2540 97–4590
Time to maximum concentration (hr)
Median 0.38 0.50 0.50 1.00 0.002
Range 0.25–0.98 0.25–3.00 0.25–2.00 0.25–2.00
Terminal elimination half-life (min)
Median 22.3 34.6 17.2 17.4 0.17
Range 8.6–180.0 8.0–105.0 7.7–82.4 9.4–62.7
AUC0–24 (hr × nM)
Median 333 616 450 880 0.14 0.01
Range 167–602 227–1320 163–969 345–2090
Dihydroartemisinin
Maximum plasma drug concentration (nM)
Median 3020 4190 2820 5590 0.50 0.11
Range 523–5690 1650–11,300 543–10,600 2950–17,900
Time to maximum concentration (hr)
Median 1.00 1.01 1.00 1.50 0.09
Range 0.48–2.98 0.48–3.00 0.50–4.00 0.42–3.00
Terminal elimination half-life (min)
Median 42.3 50.9 50.1 45.9 0.26
Range 23.8–94.6 30.1–70.8 28.1–95.1 32.4–94.3
AUC0–24 (hr × nM)
Median 4600 10,400 4860 14,500 0.34 0.04
Range 1940–9330 4770–20,000 1920–15,400 6540–19,900
* Artesunate monotherapy consisted of oral artesunate at a dose of 2 mg per kilogram of body weight per day for 7 days. Artesunate–
mefloquine therapy consisted of oral artesunate at a dose of 4 mg per kilogram per day for 3 days, followed by mefloquine at a dose of  
15 mg per kilogram on day 3 after admission and 10 mg per kilogram on day 4 after admission. AUC0–24 denotes the area under the plasma 
concentration–time curve after the first dose.
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Pailin was 1.9 nM (interquartile range, 1.3 to 3.4), 
as compared with 3.2 nM (interquartile range, 1.7 
to 4.1) in Wang Pha (P = 0.07) and 2.7 nM for the 
reference strain 3D7. The median 50% inhibitory 
concentration of dihydroartemisinin in Pailin 
was 2.3 nM (interquartile range, 1.1 to 3.2), as 
compared with 1.5 nM (interquartile range, 0.7 
to 2.2) in Wang Pha (P = 0.04) and 2.3 nM for the 
reference 3D7 (Fig. 3). There were no significant 
correlations between the 50% inhibitory concen-
tration of artesunate or dihydroartemisinin and 
the parasite clearance times in Pailin (artesu-
nate: r = 0.07, P = 0.70; dihydroartemisinin: r=0.19, 
P = 0.33) or Wang Pha (artesunate: r = 0.20, P = 0.44; 
dihydroartemisinin: r = 0.28, P = 0.23). The 50% in-
hibitory concentrations of mefloquine and chlo-
roquine did not differ significantly between the 
two study sites (Fig. 3).
Molecular Markers of Resistance
In Pailin, 38 of 40 patients (95%) had parasites that 
contained single copies of PfMDR1, and the 2 re-
maining patients (5%) had two copies, both as-
sociated with 50% inhibitory concentrations of 
mefloquine exceeding 150 nM. In Wang Pha, 18 
of the 40 patients (45%) had isolates that con-
tained multiple copies of PfMDR1 (median, 2; range, 
1 to 3; P<0.001). We did not detect any point 
mutations in the PfMDR1 gene at positions N86Y, 
S1034C, N1042D, and D1246Y, but the mutant 
codon Y184F was found in isolates from 32 of 
the 40 patients (80%) in Pailin and 12 of the 40 
patients (30%) in Wang Pha. All parasites had 
the K76T mutation in the PfCRT gene. Full-
length sequencing of the PfSERCA gene revealed 
sporadic point mutations noted as I89T (in isolates 
from 5 of 50 patients), N465S (in isolates from 
7 of 44 patients), and E847K (in isolates from 1 of 
45 patients), with similar frequencies at the two 
study sites. The number of insertion–deletion 
mutations of T-A repeats located in the intron 
region of the gene (nt3621-3671) varied among 
parasites (range, 10 to 19) but did not differ be-
tween the two sites. The PfSERCA L263E and 
S769 N polymorphisms, proposed to confer ar-
temisinin resistance, were not detected.
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Figure 3. The 50% Inhibitory Concentration (IC50) for Plasmodium falciparum, According to Antimalarial Drug.
The panels show the concentrations of chloroquine, mefloquine, dihydroartemisinin, and artesunate resulting in the 
inhibition of hypoxanthine uptake by 50% after 48 hours of in vitro culture of freshly isolated P. falciparum from the 
study patients. The horizontal lines are the medians; the I bars represent th  interquartile ranges.
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Discussion
Our study shows that P. falciparum parasites from 
patients in Pailin, western Cambodia, had signifi-
cantly reduced in vivo susceptibility to artesunate, 
as compared with parasites from northwestern 
Thailand — or indeed, apparently, anywhere else 
in the world. Artesunate resistance was charac-
terized by a markedly prolonged time to parasite 
clearance, with relatively little heterogeneity among 
patients. These reduced parasitologic responses 
could not be explained by pharmacokinetic or other 
host factors.
The principal pharmacodynamic advantage of 
using artemisinins rather than other antimalarial 
drugs is that they accelerate parasite clearance1 by 
clearing young, circulating, ring-stage parasites 
and preventing the further maturation and se-
questration of these parasites.19,20 This effect ac-
counts for the rapidity of the therapeutic response, 
its lifesaving benefit in patients with severe ma-
laria, and the notable gametocytocidal activity of 
the drugs. A few cases of reduced efficacy of 
artemisinin-based combination therapy have been 
reported previously. Most of these cases can be 
explained by the counterfeit nature of the drugs 
tested.21 In 2002–2003, decreased in vitro sensi-
tivity of P. falciparum to artemether was reported 
in French Guiana (but not in Cambodia) and was 
associated with the S769N mutation in the 
PfSERCA gene.22,23 There were no clinical corre-
lates. In our study, there was no consistent pat-
tern of PfSERCA mutations, despite clear evidence 
of in vivo artesunate resistance.
Monitoring in western Cambodia has shown 
a decline in the efficacy of artemisinin-based com-
bination therapy in recent years, but the relative 
contributions of resistance to artemisinin, the 
partner drug, and other factors have been un-
clear.7-10,24 In a recent Cambodian study, increased 
numbers of copies of the PfMDR1 gene, a well-
established cause of mefloquine resistance,18 was 
associated with high failure rates with artesunate–
mefloquine therapy.7,25 In the current study, de-
spite artesunate resistance, the efficacy of arte-
sunate–mefloquine use was excellent in Pailin 
(63-day cure rate, 95%), presumably because 
95% of parasite isolates had a single PfMDR1 
copy. PfMDR1 amplification also causes a small 
decrease in artemisinin susceptibility,18 but nei-
ther this nor any other molecular markers of 
antimalarial-drug resistance that we evaluated 
could explain the resistance to artesunate in 
Pailin.
There was an unexpected discrepancy between 
the slow clinical and parasitologic responses in 
Pailin and the relatively normal in vitro suscep-
tibility. The discrepancy can be explained by the 
reduced susceptibility of the young, ring-form 
parasites as compared with the more mature 
trophozoites and schizonts. Currently available 
in vitro susceptibility tests assess drug exposure 
over the entire parasite cycle; therefore, the re-
sults would be relatively unaffected if only part 
of the cycle were affected by the mechanism un-
derlying the resistance. Previous studies have not 
indicated significant differences in parasitologic 
responses within the dose range that we evaluat-
ed (2 to 4 mg per kilogram per day).26 A concen-
tration–effect relationship was evident in Wang 
Pha but not in Pailin, suggesting that a small 
shift to the right along the dose–response curve 
may also have occurred at the Thai–Burmese 
border.27
Chloroquine and sulfadoxine–pyrimethamine 
resistance in P. falciparum emerged in the late 
1950s and 1960s on the Thai–Cambodian border 
and spread across Asia and then Africa, contrib-
uting to millions of deaths from malaria.28,29 
Artemisinins have been available as monothera-
pies in western Cambodia for more than 30 years, 
in a variety of forms and doses, whereas in most 
countries (other than China, where they were dis-
covered), they have been a relatively recent intro-
duction.1 Despite the early implementation of an 
active malaria-control program by the Ministry 
of Health of Cambodia, including the introduc-
tion of artemisinin-based combination therapies 
in 2001, a recent survey showed that 78% of ar-
temisinin use in western Cambodia consisted of 
monotherapy provided through the private sec-
tor.30 The extended period of often-suboptimal 
use, and the genetic background of parasites from 
this region,31 might have contributed to the emer-
gence and subsequent spread of these new ar-
temisinin-resistant parasites in western Cambo-
dia. In contrast, artemisinin derivatives have been 
used almost exclusively in combination with mef-
loquine on the Thai–Burmese border, where para-
sitologic responses to artemisinins remain good, 
even after 15 years of intensive use.27 Measures 
for containment are now urgently needed to limit 
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the spread of these parasites from western Cam-
bodia and to prevent a major threat to current 
plans for eliminating malaria.
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